113. Muscular dystrophy
567 clinical trials,   442 drugs   (DrugBank: 93 drugs),   55 drug target genes,   151 drug target pathways

Searched query = "Muscular dystrophy", "Dystrophinopathies", "Myotilinopathy", "Laminopathy", "Caveolinopathy", "LGMD1C", "Desminopathy", "Sarcoglycanopathy", "α-dystroglycanopathy", "FCMD", "Walker-Warburg syndrome", "Muscle-eye-brain disease", "Myotonic dystrophy", "Integrin α7 deficient CMD", "Rigid spine syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04624750
(ClinicalTrials.gov)
November 16, 202020/10/2020Open Label Study in Adolescents and Children With Myotonic DisordersAn Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic DisordersMyotonic DystrophyDrug: MexiletineLupin Ltd.NULLNot yet recruiting6 Years18 YearsAll14Phase 3NULL
2NCT04616807
(ClinicalTrials.gov)
October 31, 202023/10/2020An Observational Study in Adult Patients With Non-dystrophic Myotonic DisordersAn Observational Study to Describe the Long-term Safety and Effectiveness of Namuscla in the Symptomatic Management of Myotonia in Adult Patients With Non-dystrophic Myotonic DisordersMyotonic DystrophyDrug: MexiletineLupin Ltd.NULLNot yet recruiting18 YearsN/AAll50NULL
3NCT01406873
(ClinicalTrials.gov)
June 201120/7/2011Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1A Randomized, Placebo Controlled, Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type-1 (DM1)Myotonic DystrophyDrug: Mexiletine;Drug: PlaceboUniversity of RochesterNULLCompleted18 Years80 YearsAll42Phase 2United States